Richard Kim

Partner

Silicon Valley / San Francisco
richard.kim2@lw.com
+1.650.470.4980

PRACTICES

  • Capital Markets
  • Mergers & Acquisitions
  • Public Company Representation

BAR QUALIFICATIONS

  • California

EDUCATION

  • JD, Georgetown University Law Center, 2009
    cum laude
  • BA in English Literature & Political Science, Colgate University, 2004
    magna cum laude

PROFILE

Richard Kim advises clients on capital markets transactions and counsels public companies within the technology and life sciences sectors.

Richard leverages a pragmatic approach and forges relationships across the capital markets space to guide issuers and investment banks on:

  • Initial public offerings (IPOs)
  • Follow-on and secondary offerings
  • Debt offerings, including convertible notes offerings

Within his public company representation practice, he develops a comprehensive understanding of his clients’ business objectives and helps them navigate complex issues relating to securities law compliance and corporate governance. Richard also represents late-stage private companies as they prepare to go public.

Richard serves on the Mentoring Committee and previously served on the Recruiting Committee.

EXPERIENCE

Richard’s experience includes representing:

IPOs and Direct Listings

  • Airbnb in its US$3.8 billion IPO
  • Amplitude in its direct listing
  • Annexon in its US$287 million IPO
  • Aratana Therapeutics in its US$39 million IPO and several subsequent public offerings
  • BIND Therapeutics in its US$76 million IPO and subsequent public offerings
  • BofA Securities in Janux Therapeutics’ US$222 million IPO
  • Goldman Sachs in PMV Pharmaceuticals’ US$243 million IPO
  • Jefferies in Reneo Pharmaceuticals’ US$93 million IPO
  • JP Morgan, BofA Merrill Lynch, Goldman Sachs, William Blair, and Cantor Fitzgerald in Glaukos’ US$124 million IPO
  • JP Morgan, Leerink Partners, William Blair, and Stifel in Inogen’s US$72 million IPO 
  • Piper Jaffray, Stifel, Leerink Partners, and William Blair in Sientra’s US$86 million IPO
  • UBS Investment Bank, Canaccord Genuity, Stifel, and BTIG in Obalon Therapeutics' US$75 million IPO

Follow-On and Secondary Offerings

  • BofA Merrill Lynch, JP Morgan, Morgan Stanley, Barclays, and Deutsche Bank Securities in BioMarin Pharmaceutical’s US$911 million follow-on offering
  • BofA Securities, Jefferies, SVB Securities, Evercore ISI, and Guggenheim Securities in Vaxcyte’s US$600 million public offering
  • Cantor Fitzgerald in Corium International’s US$20 million follow-on offering 
  • Jefferies, Leerink Partners, and Wells Fargo Securities in Immune Design’s US$32 million follow-on offering
  • JP Morgan, Cowen, Stifel, Wells Fargo Securities, and SunTrust Robinson Humphrey in Array Biopharma’s US$132 million follow-on offering of Array Biopharma
  • Piper Jaffray and William Blair in LDR’s US$92 million follow-on offering of LDR
  • Puma Biotechnology on several public offerings 

Debt Offerings

  • Airbnb in its US$2 billion convertible senior notes offering
  • AMD in its US$1 billion senior notes offering
  • Eventbrite in its:
    • US$150 million convertible senior notes offering
    • US$212 million convertible senior notes offering